Biotech - Technical Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JEB who wrote (164)	3/13/2002 2:09:41 PM
From: Jibacoa	Read Replies (1) of 544

Yes, results, were impressive, especially at the end of 18 months.(7 to 1 ratio) Albeit the number of patients was small (21 patients receiving full treatment and only 10 controls).<g> At the end of the 6-month, treatment-free follow-up period, 76% of patients receiving ZADAXIN plus interferon showed a sustained response, as measured by normalization of ALT and disappearance of hepatitis B virus DNA. By comparison, only 40% of patients receiving interferon monotherapy showed a sustained response after the 6-month follow-up period. When patients were observed for an additional 12-month follow-up period, 71% of patients receiving ZADAXIN plus interferon still showed a sustained response, versus only 10% of the patients receiving interferon monotherapy. It looks like the stock will easily close above 4.<g> siliconinvestor.com And it should have a chance to test the 6 level for a 50% gain.<g> siliconinvestor.com The stock is up 40% today and volume is 10x its daily average.<g> The insiders only hold 2%. Institutions had been doing some buying lately. I didn't have SCLN on my "watch list" an missed today's early buy signal.<g> siliconinvestor.com RAGL Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next